22 May 2013
Keywords: imutec, suspends, virulizin, trials, canadian, biotechnology, firm
Article | 31 July 1995
Canadian biotechnology firm Imutec has suspended all clinical trials of
its anticancer drug Virulizin in a major restructuring drive. This
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
There are no related articles.
21 May 2013
© 2013 thepharmaletter.com